{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:41:48Z","timestamp":1791513708275,"version":"4.3.4"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1093\/rheumatology\/kep306","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T02:48:16Z","timestamp":1254883696000},"page":"5-14","source":"Crossref","is-referenced-by-count":50,"title":["The modern management of gout"],"prefix":"10.1093","volume":"49","author":[{"given":"Tom G.","family":"Rider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey M.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,10,5]]},"reference":[{"key":"key\n\t\t\t\t20170225065940_B1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1906","article-title":"A concise history of gout and hyperuricemia and their treatment","volume":"8","author":"Nuki","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20170225065940_B2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/ard.2007.076232","article-title":"Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005","volume":"67","author":"Annemans","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170225065940_B3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":"Gout epidemiology: results from the UK general practice research database, 1990\u20131999","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170225065940_B4","first-page":"1346","article-title":"The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China","volume":"33","author":"Nan","year":"2006","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20170225065940_B5","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/archinte.156.20.2381","article-title":"Hyperuricemia among Kuwaitis","volume":"156","author":"Ali","year":"1996","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170225065940_B6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/ajcn\/78.4.690","article-title":"A case-control of the association of diet and obesity with gout in Taiwan","volume":"78","author":"Lyu","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"key\n\t\t\t\t20170225065940_B7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.23245","article-title":"Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the third national health and nutrition examination survey","volume":"59","author":"Woong","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170225065940_B8","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guidelines for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20170225065940_B9","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)","volume":"65","author":"Zang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170225065940_B10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/ard.2007.070755","article-title":"Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations","volume":"66","author":"Roddy","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170225065940_B11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170225065940_B12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"key\n\t\t\t\t20170225065940_B13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.ackd.2006.01.008","article-title":"Genetic factors associated with gout and hyperuricemia","volume":"13","author":"Bleyer","year":"2006","journal-title":"Adv Chronic Kidney Dis"},{"key":"key\n\t\t\t\t20170225065940_B14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0033-8389(03)00158-1","article-title":"Gout: a clinical and radiologic review","volume":"42","author":"Monu","year":"2004","journal-title":"Radiol Clin North Am"},{"key":"key\n\t\t\t\t20170225065940_B15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1908","article-title":"The inflammatory process of gout and its treatment","volume":"8","author":"Cronstein","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20170225065940_B16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jbspin.2007.04.004","article-title":"The inflammasome, autoinflammatory diseases, and gout","volume":"74","author":"P\u00e9trillie","year":"2007","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20170225065940_B17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate-anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170225065940_B18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/art.21499","article-title":"Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population","volume":"54","author":"Graessler","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170225065940_B19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/ken460","article-title":"Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout","volume":"48","author":"Dalbeth","year":"2009","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20170225065940_B20","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170225065940_B21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","article-title":"Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study","volume":"336","author":"Choi","year":"2008","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170225065940_B22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170225065940_B23","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/art.22712","article-title":"Coffee consumption and risk of incident gout in men","volume":"56","author":"Choi","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170225065940_B24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.165.7.742","article-title":"Obesity, weight change, hypertension, diuretic use, and risk of gout in men","volume":"165","author":"Choi","year":"2005","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170225065940_B25","first-page":"1853","article-title":"Vitamin C intake and serum uric acid concentration in men","volume":"35","author":"Gao","year":"2008","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20170225065940_B26","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/jn\/133.6.1826","article-title":"Consumption of cherries lowers plasma urate in healthy women","volume":"133","author":"Jacob","year":"2003","journal-title":"J Nutr"},{"key":"key\n\t\t\t\t20170225065940_B27","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.2174\/138161205774913273","article-title":"Dietary factors and hyperuricaemia","volume":"11","author":"Schlesinger","year":"2005","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t20170225065940_B28","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/rheumatology\/ken305","article-title":"Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile","volume":"47","author":"Choi","year":"2008","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20170225065940_B29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2125.1987.tb03132.x","article-title":"Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs","volume":"24","author":"Bellamy","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170225065940_B30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/01.rhu.0000249864.95389.cf","article-title":"Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides","volume":"12","author":"Schlesinger","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"key\n\t\t\t\t20170225065940_B31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003495-200868040-00002","article-title":"Overview of the management of acute gout and the role of adrenocorticotropic hormone","volume":"68","author":"Schlesinger","year":"2008","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170225065940_B32","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kem090","article-title":"Lumiracoxib 400mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout","volume":"46","author":"Willburger","year":"2007","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20170225065940_B33","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","article-title":"Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis","volume":"324","author":"Schumacher","year":"2002","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170225065940_B34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","article-title":"Does colchicine work? The results of the first controlled study in acute gout","volume":"17","author":"Ahern","year":"1987","journal-title":"Aust N Z J Med"},{"key":"key\n\t\t\t\t20170225065940_B35","article-title":"Low dose (1.8 mg) vs high dose (4.8 mg) oral colchicine regimens in patients with acute gout flare in a large, multicenter, randomized, double-blind, placebo-controlled, parallel group study. In: ACR Conference Proceedings","author":"Terkeltaub","year":"2008","journal-title":"Abstract 1944"},{"key":"key\n\t\t\t\t20170225065940_B36","first-page":"204","article-title":"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin","volume":"66","author":"Van der Velden","year":"2008","journal-title":"J Med"},{"key":"key\n\t\t\t\t20170225065940_B37","article-title":"A one sequence, two-period pharmacokinetic drug-drug interaction study with colchicine reveals profound effects of clarithromycin (a macrolide antibiotic) on the pharmacokinetic profile of colchicine in healthy adults. In: ACR Conference Proceedings","author":"Terkeltaub","year":"2008","journal-title":"Abstract 1946"},{"key":"key\n\t\t\t\t20170225065940_B38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/14740338.6.6.625","article-title":"Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment","volume":"6","author":"Schlesinger","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"key\n\t\t\t\t20170225065940_B39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2007.05.019","article-title":"Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists","volume":"15","author":"Stahn","year":"2007","journal-title":"Mol Cell Endocrinol"},{"key":"key\n\t\t\t\t20170225065940_B40","first-page":"111","article-title":"Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis","volume":"20","author":"Alloway","year":"1993","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20170225065940_B41","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","article-title":"Comparison of oral prednisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute gout like arthritis: a double-blind, randomized, controlled trial","volume":"49","author":"Man","year":"2007","journal-title":"Ann Emerg Med"},{"key":"key\n\t\t\t\t20170225065940_B42","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170225065940_B43","article-title":"Systemic corticosteroids for acute gout","author":"Janssens","journal-title":"Cochrane Database"},{"key":"key\n\t\t\t\t20170225065940_B44","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/ard.2007.073759","article-title":"Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra","volume":"66","author":"McGonagle","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170225065940_B45","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20170225065940_B46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170225065940_B47","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20170225065940_B48","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/13543784.14.7.893","article-title":"Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout","volume":"14","author":"Schumacher","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t20170225065940_B49","first-page":"122","article-title":"Alternative urate-lowering drugs and the management of hyperuricemia in allopurinol-intolerant patients","volume":"1","author":"Fam","year":"2003","journal-title":"Int J Adv Rheumatol"},{"key":"key\n\t\t\t\t20170225065940_B50","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sciences"},{"key":"key\n\t\t\t\t20170225065940_B51","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170225065940_B52","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/875512250602200607","article-title":"Febuxostat: a novel, non-purine xanthine oxidase inhibitor","volume":"22","author":"Kim","year":"2006","journal-title":"J Pharm Technol"},{"key":"key\n\t\t\t\t20170225065940_B53","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170225065940_B54","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-year findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20170225065940_B55","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170225065940_B56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ncprheum0214","article-title":"Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol","volume":"2","author":"Richette","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"key\n\t\t\t\t20170225065940_B57","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout","volume":"8","author":"Lee","year":"2008","journal-title":"Drug Safety"},{"key":"key\n\t\t\t\t20170225065940_B58","first-page":"1528","article-title":"Benzbromarone therapy in management of refractory gout","volume":"118","author":"Kumar","year":"2005","journal-title":"N Z Med J"},{"key":"key\n\t\t\t\t20170225065940_B59","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1371\/journal.pmed.0050197","article-title":"SLC2A9 is a high-capacity urate transporter in humans","volume":"5","author":"Caulfield","year":"2008","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20170225065940_B60","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.rdc.2006.03.003","article-title":"Treatment of crystal arthropathy\u2014history and advances","volume":"32","author":"Nuki","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"key\n\t\t\t\t20170225065940_B61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170225065940_B62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.rdc.2005.10.003","article-title":"Newer therapeutic approaches: gout","volume":"32","author":"Schumacher","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"key\n\t\t\t\t20170225065940_B63","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","article-title":"Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients","volume":"26","author":"Reinders","year":"2007","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t20170225065940_B64","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout","volume":"20","author":"Vogt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170225065940_B65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"key\n\t\t\t\t20170225065940_B66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7150\/ijms.4.83","article-title":"Rasburicase represents a new tool for hyperuricemia in tumour lysis syndrome and in gout","volume":"2","author":"Cammalleri","year":"2007","journal-title":"Int J Med Sci"},{"key":"key\n\t\t\t\t20170225065940_B67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.rdc.2005.10.003","article-title":"Newer therapeutic approaches: gout","volume":"32","author":"Schumacher","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"key\n\t\t\t\t20170225065940_B68","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/0091270008317589","article-title":"Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout","volume":"48","author":"Yue","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170225065940_B69","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout","volume":"20","author":"Vogt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170225065940_B70","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"key\n\t\t\t\t20170225065940_B71","article-title":"Immunoreactivity and clinical response to pegloticase (PGL): pooled data from gout1 and gout2, PGL phase 3 randomized, double blind, placebo-controlled trials. In: ACR Conference Proceedings","author":"Becker","year":"2008","journal-title":"Abstract 1945"},{"key":"key\n\t\t\t\t20170225065940_B72","article-title":"Tophus response to pegloticase (PGL) therapy: pooled results from gout1 and gout2, PGL phase 3 randomized, double blind, placebo-controlled trials. In: ACR Conference Proceedings","author":"Baraf","year":"2008","journal-title":"Abstract 22"},{"key":"key\n\t\t\t\t20170225065940_B73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3904\/kjim.2006.21.2.89","article-title":"Effect of fenofibrate in combination with urate lowering agents in patients with gout","volume":"21","author":"Lee","year":"2006","journal-title":"Korean J Intern Med"},{"key":"key\n\t\t\t\t20170225065940_B74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5414\/CPP44022","article-title":"Effects of a fenofibrate\/losartan combination on the plasma concentration and urinary excretion of purine bases","volume":"44","author":"Ka","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170225065940_B75","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/ard.2007.076182","article-title":"Uric acid lowering therapy: prescribing patterns in a large cohort of older adults","volume":"67","author":"Solomon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170225065940_B76","first-page":"1038","article-title":"Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK general practice research database","volume":"44","author":"Mikuls","year":"2005","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/49\/1\/5\/10652483\/kep306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T01:32:23Z","timestamp":1558575143000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/1789129\/The"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,5]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,10,5]]},"published-print":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kep306","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"value":"1462-0332","type":"electronic"},{"value":"1462-0324","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10,5]]}}}